InnoCare Pharma (SHSE:688428) Tariff Resilience Score: 0/10 (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688428 InnoCare Pharma Ltd SHSE:688428
74 GF Score
Price ¥29.60
GF Value ¥34.11
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is InnoCare Pharma Tariff Resilience Score?

InnoCare Pharma has the Tariff Resilience Score of 0, which implies that the company might have .

InnoCare Pharma has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes InnoCare Pharma might have .


InnoCare Pharma  (SHSE:688428) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

InnoCare Pharma Tariff Resilience Score Related Terms

SHSE:688428
74GF Score
InnoCare Pharma Ltd SHSE:688428
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is InnoCare Pharma (SHSE:688428) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued. The current stock price of ¥29.60 is trading 13.2% below its estimated GF Value™ of ¥34.11. GuruFocus considers InnoCare Pharma to be Modestly Undervalued.

Key valuation signals for SHSE:688428:

  • Tariff Resilience Score: 0
  • GF Value™: ¥34.11 vs. price of ¥29.60 (13.2% below fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688428 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InnoCare Pharma Business Description

Other Exchanges 09969:Hong Kong33C:Germany
Address No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
74GF Score

Get the complete analysis for SHSE:688428

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥29.60
Price
¥34.11
GF Value